FDA Approves New Indication for Myrbetriq in Children With NDO

FRIDAY, March 26, 2021 -- Myrbetriq (mirabegron extended-release tablets) is now approved for treatment of neurogenic detrusor overactivity, common in patients with spina bifida, in children 3 years and older, the U.S. Food and Drug Administration...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news